[1] 林世德,罗亚文,苏毅,等. 肝衰竭研究进展.实用肝脏病杂志,2009,12(1):73-75. [2] 陈从新,郭顺明,刘波,等. 糖皮质激素阻断慢性乙型肝炎肝衰竭发生的临床对照观察. 中华肝脏病杂志,2003,11(1):37-39.[3] 骆抗先. 乙型肝炎基础和临床.北京,人民卫生出版社,1997:213. [4] 中华医学会传染病与寄生虫病学分会及肝病学分会.病毒性肝炎防治方案. 中华肝脏病杂志,2000,8(6):324-329. [5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2010年版). 实用肝脏病杂志,2011,14(2):81-89. [6] 全国传染病、寄生虫病学术会议. 病毒性肝炎防治方案.中华内科杂志,1995,34(11):788-791. [7] 中华医学会感染病学分会肝衰竭与人工肝学组和肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南. 实用肝脏病杂志,2006,9(6):321-324. [8] Trey C,Davidson CJ. The management of fulminant hepatic failure in progress in liver diseases,Vol. 3. H Popper,F Schaffner (eds). New York,Grune and Stratton,1970,282-298. [9] 聂广. 肝衰竭的分型、分期与分级.全国中西医结合肝病新进展讲习班. 江西省第二次中西医结合肝病学术会议资料汇编.2010:124. [10] Higgins J,Green S.Cochrane Collaboration:Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March2011].John Wiley Sons Ltd and The Cochrane Collaboration,Chichester,2011. [11] 李静,李幼平. 不断完善与发展的Cochrane系统评价. 中国循证医学杂志,2008,8(9):742-743. [12] 马捷,刘莹,钟来平,等.Jadad量表与Cochrane偏倚风险评估工具在随机对照试验质量评价中的应用与比较. 中国口腔颌面外科杂志,2012,10:417-422. [13] Higgim JP,Airman DG,Gotzsche PC,et a1.The Cochrane CoUabomtion’Stool for assessing risk of bias in randomised trials.BMJ,201l,343:d5928. [14] 丁虹,董峰. 拉米夫定与糖皮质激素治疗慢性重型乙型肝炎的疗效观察.肝脏,2008,13(1):93-94. [15] 李映菊,汪煜华,彭忠田. 糖皮质激素治疗早期肝衰竭最佳方案初探.南华大学学报·医学版,2010,38(1):80-83. [16] 刘波,董静,杨家宏,等. 糖皮质激素联合生长激素治疗慢加亚急性肝衰竭临床观察.实用肝脏病杂志,2009,12(5):350-354. [17] 彭伟明,于强,席启辉,等. 拉米夫定联合地塞米松辅助治疗肝衰竭疗效观察.人民军医,2012,55(10):983-984. [18] 周先珊,万谟彬,薛建亚,等. 抗病毒基础上应用糖皮质激素治疗慢性重型乙型肝炎临床分析. 临床肝胆病杂志,2008,24 (2):101-103. [19] 谭善忠,徐乾,杨觉民,等. 足三里穴位注射小剂量地塞米松治疗肝衰竭早期疗效分析. 中西医结合肝病杂志,2009,19(4):242-244. [20] 吴锦瑜,黎明,张华. 糖皮质激素治疗对早期肝衰竭患者转归的影响.南方医科大学学报,2011,31(3):554-556. [21] 叶崎,沈芝仙,王美娟. 甲基强的松龙治疗肝衰竭的临床分析及护理. 第1届全国肝病治疗进展与临床药学学术研讨会论文集,2009:54-56. [22] 朱理辉,张琍,李国庆,等.地塞米松早期治疗病毒性肝炎重型倾向的近期疗效观察.临床肝胆病杂志,2011,27(12):1305-1307. [23] Zhang XQ,Jiang L,You JP,et al. Efficacy of short term dexamethasone therapy in acute-on-chronic pre-liver failure. Hepatol Res,2011,41:46-53. [24] Zhao J,Zhang JY,Yu HW,et al. Improved survival ratios correlate with myeloid dendritic cell restoration in acute-on-chronic liver failure patients receiving methylprednisolone therapy. Cell Mol Immunol,2012,9:417-422. [25] Rakela J,Mosley JM,Edward VM,et al. A double-blinded,randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group. Dig Dis Sci,1991,36(9):1223-1228. [26] Gregory PB,Knauer CM,Kempson RL,et al. Steroid therapy in severe viral hepatitis. N Engl J Med,1976,294:681-687. [27] Greenberg HB,Robinson WS,Michael Knauer C,et al. Hepatitis B viral markers in severe viral hepatitis:influence of steroid therapy. Hepatology,1981,1:54-57. [28] Ware A,Cuthbert J,Shorey J,et al. A prospective trial of steroid therapy in severe viral hepatitis. The prognostic significance of bridging necrosis. Gastroenterology,1981,80:219-224. [29] 张绪清,聂青和. 糖皮质激素在治疗肝衰竭中的应用及评价.实用肝脏病杂志,2004,7(2):70-72. |